Literature DB >> 15878004

Influence of the randomized trials, AFFIRM and RACE, on the management of atrial fibrillation in two University Medical Centers.

Pamela K Mason1, Mark A Wood, Douglas Lake, John P Dimarco.   

Abstract

The results of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) and the Rate Control Versus Electrical Cardioversion for Persistent Atrial Fibrillation (RACE) study were presented in March 2002. These large studies showed no benefit of a rhythm-control strategy over a rate-control strategy in managing atrial fibrillation (AF). Cardioversion and atrioventricular junctional ablation are forms of rhythm control and rate control, respectively. The numbers of cardioversions and atrioventricular junctional ablations performed at the University of Virginia and the Medical College of Virginia during the 52 months before AFFIRM and RACE results were released and the 21 months afterward were compared. From January 1998 to March 2002, monthly averages of 31 +/- 8 elective cardioversions and 6 +/- 3 atrioventricular junctional ablations were performed; from April 2002 to December 2003, the monthly averages were 21 +/- 6 cardioversions (p = 0.001) and 9 +/- 3 ablations (p = 0.001). AF management changed at these institutions shortly after the RACE and AFFIRM results were released.

Entities:  

Mesh:

Year:  2005        PMID: 15878004     DOI: 10.1016/j.amjcard.2005.01.059

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  3 in total

1.  Trends in US hospitalization rates and rhythm control therapies following publication of the AFFIRM and RACE trials.

Authors:  William Martin-Doyle; Vidal Essebag; Peter Zimetbaum; Matthew R Reynolds
Journal:  J Cardiovasc Electrophysiol       Date:  2010-11-18

2.  Rhythm- or rate-control strategies according to 4S-AF characterization scheme and long-term outcomes in atrial fibrillation patients: the FAMo (Fibrillazione Atriale in Modena) cohort.

Authors:  Gregory Y H Lip; Giuseppe Boriani; Vincenzo L Malavasi; Marco Vitolo; Jacopo Colella; Francesca Montagnolo; Marta Mantovani; Marco Proietti; Tatjana S Potpara
Journal:  Intern Emerg Med       Date:  2021-12-02       Impact factor: 5.472

3.  Trends in the use of electrical cardioversion for atrial fibrillation: influence of major trials and guidelines on clinical practice.

Authors:  Josep M Alegret; Xavier Viñolas; César Romero-Menor; Silvia Pons; Roger Villuendas; Naiara Calvo; Jordi Pérez-Rodon; Xavier Sabaté
Journal:  BMC Cardiovasc Disord       Date:  2012-06-18       Impact factor: 2.298

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.